ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
61 announcements with these filters
Gland Pharma announced a long-term strategic CDMO partnership with Neuland Laboratories to expand its sterile API manufacturing infrastructure at its Visakhapatnam facility.
Gland Pharma Limited submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026, as per SEBI regulations.
Gland Pharma has issued a notice for its 48th Annual General Meeting to be held on August 25, 2026. The meeting agenda includes dividend declaration and director reappointments.
Gland Pharma Limited announced the grant of 16,790 employee stock options to 3 employees under the Gland Pharma Employee Stock Option Scheme 2025.
Gland Pharma received USFDA approval for Sugammadex Injection single-dose vials. The product has been successfully launched via its marketing partner.
Gland Pharma Limited has scheduled a board meeting on August 10, 2026, to consider and approve its unaudited standalone and consolidated financial results.
Gland Pharma shareholders approved the reappointment of Udo Jahannes Vetter and the appointment of William Robert Keller as Independent Directors for five-year terms.
Gland Pharma Limited announced the results of the Postal Ballot, where all proposed resolutions regarding the appointment and remuneration of Independent Directors were passed.
Gland Pharma submitted its quarterly shareholding pattern for the period ending June 30, 2026. This is a routine regulatory disclosure.
Gland Pharma received a ₹7.06 Crore demand and penalty notice from Customs Authorities. The company plans to appeal, citing no material financial impact.
Gland Pharma received a Rs. 7.06 Crore demand from Customs Authority, including IGST and penalties. The company intends to appeal against the order.
Mirae Asset Mutual Fund sold a 0.18% stake in Gland Pharma via open market. Its holding decreased from 5.17% to 4.98%.
Independent Director Mr. Satyanarayana Murthy Chavali resigned due to potential conflict of interest. His departure effective June 15, 2026, ensures governance standards.
Gland Pharma's board approved re-appointment of an independent director, appointed a new independent director, and accepted a resignation. These changes strengthen board governance with experienced pharmaceutical leaders.
Gland Pharma allotted 2,03,259 equity shares following the exercise of employee stock options. This issuance raised approximately ₹1.04 Crore and increased the total paid-up share capital.
Gland Pharma filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms full compliance with SEBI regulations and listing requirements.
Gland Pharma reported record quarterly revenue of INR 17,428M (+22% YoY) for Q4FY26, driven by CDMO growth and the Cenexi turnaround. FY26 adjusted PAT reached INR 10,455M with a 16% margin.
Gland Pharma reports a recovery quarter with consolidated revenue up 7% and a sharp 39% EBITDA jump, primarily driven by Cenexi reaching EBITDA break-even and lower raw material costs.
Gland Pharma reports strong FY26 performance with 14% revenue growth and 50% Adj. PAT growth, driven by US market gains and Cenexi recovery.
Gland Pharma Ltd reported revenue from operations of ₹1,743 Cr (+22.3% YoY) and net profit of ₹366.7 Cr (+96.6% YoY) for Q4 FY26.
Gland Pharma Limited reappointed Ms. Naina Lal Kidwai as Independent Director for five years starting May 2026. The reappointment ensures leadership stability and strong corporate governance.
Gland Pharma Limited announced the successful reappointment of Ms. Naina Lal Kidwai as an Independent Director through postal ballot. Shareholders approved the resolution with requisite majority.
Gland Pharma convened an ESOP Compensation Committee meeting for May 15, 2026. The committee will consider granting stock options under its 2025 employee incentive scheme.
Gland Pharma Limited clarified its postal ballot notice regarding Ms. Naina Lal Kidwai's reappointment. The company will obtain annual special resolutions from members if her remuneration exceeds 50% of the total Non-Executive Director pay for the FY 2026-2031 period.
Gland Pharma Limited has scheduled a Board Meeting for May 15, 2026, to consider audited standalone and consolidated financial results for the year ended March 2026. The board will also consider a recommendation for a final dividend. The trading window is closed from March 28, 2026, until May 17, 2026.
Gland Pharma Limited has scheduled a Board Meeting for May 15, 2026, to approve audited financial results for FY 2025-26 and consider a final dividend. The company's trading window remains closed until May 18, 2026. An earnings call is also scheduled for the evening of May 15.
Gland Pharma Limited has issued a postal ballot notice to shareholders for the re-appointment of Ms. Naina Lal Kidwai as an Independent Director. The special resolution also proposes commission on profits as remuneration. Voting will be conducted virtually from April 14, 2026, to May 13, 2026.
Gland Pharma Limited has issued a postal ballot notice seeking shareholder approval to reappoint Ms. Naina Lal Kidwai as an Independent Director for a second five-year term starting May 17, 2026. The resolution includes a proposed commission of 0.25% on net profits, capped at ₹1 Crore annually. Remote e-voting remains open from April 14 to May 13, 2026.
Gland Pharma Limited has re-appointed Ms. Naina Lal Kidwai as a Non-Executive Independent Director for a five-year term effective May 17, 2026. A Padma Shri recipient and former HSBC India Chairman, her extensive leadership experience across finance and industry continues to strengthen the company's board governance.
Gland Pharma Limited's Board approved the reappointment of Ms. Naina Lal Kidwai as an Independent Director for a second five-year term, effective May 17, 2026, to May 16, 2031. The reappointment is subject to shareholder approval via postal ballot.